| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/08/2002 | DE10053496A1 Zusammensetzungen enthaltend Flavonoide und Phloridzin oder Phloretin Compositions containing flavonoids and phloretin or phloridzin |
| 05/08/2002 | DE10053155A1 Treatment of psoriasis comprises administration of a multivitamin preparation containing vitamins B1, B2, B6, B12, C and E, nicotinamide, dexpanthenol, biotin and folic acid |
| 05/08/2002 | CN1348466A Epitopes or mimotopes derived from the c-epsilon-2-domain of IgE, antagonists thereof, and their therapeutic uses |
| 05/08/2002 | CN1348465A Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| 05/08/2002 | CN1348385A Preventives/remedies/progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 05/08/2002 | CN1348384A An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport |
| 05/08/2002 | CN1348374A Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4-metabolic pathway, and inhibitors of lipid metabolism |
| 05/08/2002 | CN1348372A 药物用途 Drug use |
| 05/08/2002 | CN1348370A Cyclic protein tyrosine kinase inhibitors |
| 05/08/2002 | CN1348369A Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/08/2002 | CN1348363A Novel pharmaceutical salt form |
| 05/08/2002 | CN1348334A Dietary compositions and methods |
| 05/08/2002 | CN1347734A Method for treating thrombosis diseases |
| 05/07/2002 | US6384081 Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| 05/07/2002 | US6384079 Topically effective, skin-treating composition prepared by combining nystatin and/or hormone and enhancing amount of member selected from hydroxycarboxylic acids, lactones or salts and related ketocarboxylic acids, esters or salts |
| 05/07/2002 | US6384064 Human immunodeficiency syndrone, hepatitis virus |
| 05/07/2002 | US6384062 Pharmaceutical composition |
| 05/07/2002 | US6384052 Anticoccidial compounds |
| 05/07/2002 | US6384049 Cancer treatment |
| 05/07/2002 | US6384042 Systemic use of 5-HT3 receptor antagonists against rheumatic inflammatory processes |
| 05/07/2002 | US6384039 QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death |
| 05/07/2002 | US6384038 Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| 05/07/2002 | US6384034 Method of treating migraines and pharmaceutical compositions |
| 05/07/2002 | US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383768 Method for producing in vitro the RNA-dependent RNA polymerase and terminal nucleotidyl transferase activities encoded by hepatitis C virus (HCV) |
| 05/07/2002 | US6383760 Contacting receptor with test compound, then determining if compound binds to receptor |
| 05/07/2002 | US6383733 Methods of screening for pharmacologically active compounds for the treatment of tumour diseases |
| 05/07/2002 | US6383529 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 05/07/2002 | US6383527 For treatment of acute muscular aches, strains, and sprains which occur from a localized, external insult to a particular muscle or muscle group |
| 05/07/2002 | US6383523 Cleaning compounds |
| 05/07/2002 | US6383522 Toxicity reduced composition containing an anti-neoplastic agent and a shark cartilage extract |
| 05/07/2002 | US6383512 For delivering to cell a composition comprising local anesthetic and nucleic acid molecules that comprise a nucleotide sequence that encodes an antisense oligonucleotide, a ribozyme, and a triplex forming nucleic acid |
| 05/07/2002 | US6383511 Local prevention or amelioration of pain from surgically closed wounds |
| 05/07/2002 | US6383499 Topical medicament for the treatment of psoriasis |
| 05/07/2002 | CA2361071A1 Combination therapies for the stimulation of bone growth |
| 05/07/2002 | CA2348845A1 Adenosine as antithrombotic |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/07/2002 | CA1341357C Platelet-specific chimeric immunoglobulin |
| 05/06/2002 | WO2002038178A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |
| 05/06/2002 | CA2429404A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |
| 05/03/2002 | WO2002035962A1 Hair clip |
| 05/03/2002 | CA2377219A1 Hair clip |
| 05/02/2002 | WO2002035240A2 Methods for identifying compounds for regulating muscle mass or function using vasoactive intestinal peptide receptors |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034922A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 05/02/2002 | WO2002034914A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | WO2002034913A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 05/02/2002 | WO2002034903A2 Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications |
| 05/02/2002 | WO2002034899A2 Tec kinase assay |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034289A1 Modulating angiogenesis |
| 05/02/2002 | WO2002034288A2 Vaccine for treating allergy |
| 05/02/2002 | WO2002034284A2 Methods of therapy for hiv infection |
| 05/02/2002 | WO2002034280A2 Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain |
| 05/02/2002 | WO2002034276A2 Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid |
| 05/02/2002 | WO2002034274A1 A composition or rose hip and fish oil for alleviating joint pain and stiffness |
| 05/02/2002 | WO2002034273A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | WO2002034272A2 Methods of improving central nervous system functioning |
| 05/02/2002 | WO2002034270A1 Treatment of respiratory distress syndrome with powder surfactant composition |
| 05/02/2002 | WO2002034269A1 Method for the preparation of a pharmaceutical composition, and its use |
| 05/02/2002 | WO2002034267A1 Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states |
| 05/02/2002 | WO2002034262A1 Combination of catechin and quercetin for pharmaceutical or dietary use |
| 05/02/2002 | WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 05/02/2002 | WO2002034255A1 Granular drug preparations containing branched amino acids and process for producing the same |
| 05/02/2002 | WO2002034249A1 Treatment of pcp addiction and pcp addiction-related behavior |
| 05/02/2002 | WO2002034248A2 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION |
| 05/02/2002 | WO2002034243A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034242A2 Method for the treatment of neurological and neuropsychological disorders |
| 05/02/2002 | WO2002034235A1 Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034201A2 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | WO2002034199A2 Medicine intended for treatment of multiple sclerosis |
| 05/02/2002 | WO2002034119A2 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | WO2002034073A2 Compositions containing flavonoids and phlorizin or phloretin |
| 05/02/2002 | WO2002019812A3 Mutant non-human mammal for expressing the alpha6 acetylcholine nicotinic receptor subunit and use for screening substances capable of interacting with said receptor |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2002011677A3 Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| 05/02/2002 | WO2002006460A3 Masp-2, a complement-fixing enzyme, and uses for it |
| 05/02/2002 | WO2002005829A3 Methods and formultations with probiotic microorganisms and medicaments |
| 05/02/2002 | WO2002002103A3 Compositions based on aminoacids, suitable for the treatment of heart failure |
| 05/02/2002 | WO2002002091A3 Methods and compositions for the treatment of alcoholism and alcohol dependence |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096283A3 Hiv integrase inhibitors |
| 05/02/2002 | WO2001090074A3 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) |
| 05/02/2002 | WO2001085165A3 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 05/02/2002 | WO2001083555A3 Pain signaling molecules |
| 05/02/2002 | WO2001074900A3 Nuclear factor kb inducing factor |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001070771A3 Acute neuronal induced calcium binding protein type 1 ligand |
| 05/02/2002 | WO2001066772A3 Heparinase iii and uses thereof |
| 05/02/2002 | WO2001064741A3 Methods for selectively modulating survivin apoptosis pathways |
| 05/02/2002 | WO2001062931A3 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062289A3 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 05/02/2002 | WO2001062266A3 Use of dpp-iv inhibitors for the treatment of diabetes |
| 05/02/2002 | WO2001055393A3 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |